Video

Rakesh Jetly, MD: The Balance of PTSD Treatment

Author(s):

New study will look at psychedelics as a treatment for PTSD.

For a treatment regimen to be successful for post traumatic stress disorder (PTSD) it must include both a pharmacologic portion and a non-pharmacologic therapeutic part.

In an interview with HCPLive®, Rakesh Jetly, MD, Head of the Center of Excellence on Mental Health, explained how both parts of the therapy are necessary.

Jetly is part of an ongoing trial testing psychedelic substances as a viable treatment for PTSD. While he hypothesizes the treatment could be safe and effective, it is unknown whether it could eventually move to the front of the line for PTSD treatments.

However, he does believe psychosubstances do show promise in allowing the patient to better manage their traumatic memories that are causing the symptoms of PTSD.

The study is looking at low-dose psychosubstances for veterans with PTSD. Because much of what veterans go through during combat causes long-lasting pain issues, there is the potential this treatment can help reduce the amount of veteran patients dependent on opioids for pain relief.

Another byproduct of the study testing psychedelics in PTSD patients is researchers may learn more about the brain and why it responds to certain treatments but not others.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
© 2024 MJH Life Sciences

All rights reserved.